Men’s Health spoke to Novo Nordisk's Thomas Kruse and Jesper Lau, the two chemists responsible for discovering semaglutide—the main ingredient in Ozempic and Wegovy.

Novo Nordisk is working with OpenAI on a broad deal that will use artificial intelligence to more quickly develop new medications as well as help train its workforce. Novo Nordisk’s U.S.-listed shares ...

Lilly will hope Foundayo continues its growing dominance over Novo Nordisk in the obesity drug market. Credit: Michael Vi/Shutterstock.com. The US Food and Drug Administration (FDA) has approved Eli ...

Still basking in the afterglow of its Wegovy pill launch earlier this year, Novo has achieved another victory as it strives to make the most out of its blockbuster GLP-1 drug in an increasingly ...

First, let me preface this analysis by stating that I hold some Novo Nordisk A/S (NVO) stock, acquired at around this time last year - and in the 12 months since, my position has halved in value.

Among the unreported adverse events potentially linked to Ozempic are two deaths and one case of “completed suicide,” according to an FDA inspection report. Novo Nordisk received a warning letter last ...

Just when you think Novo Nordisk A/S (NVO) can't go any lower, it gets some more bad news, and the stock dips further. The stock already collapsed in 2025 as GLP-1 enthusiasm faded and political ...

The weight-loss drugs that kicked off America's GLP-1 craze are about to get a lot less expensive, though only certain customers will notice the savings. Novo Nordisk said it will slash list prices of ...

Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...

Novo's drug, CagriSema, didn't achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly's rival drug tirzepatide. The stock plummeted on Monday, hitting its ...

Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments. Doustdar said he doesn't expect Medicare access to ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...